207 related articles for article (PubMed ID: 26334991)
1. Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
Gutzwiller FS; Pfeil AM; Ademi Z; Blank PR; Braunhofer PG; Szucs TD; Schwenkglenks M
Pharmacoeconomics; 2015 Dec; 33(12):1311-24. PubMed ID: 26334991
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.
Koiwa F; Yokoyama K; Fukagawa M; Terao A; Akizawa T
Nephrology (Carlton); 2017 Apr; 22(4):293-300. PubMed ID: 27496336
[TBL] [Abstract][Full Text] [Related]
3. Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients.
Nguyen HV; Bose S; Finkelstein E
BMC Nephrol; 2016 Apr; 17(1):45. PubMed ID: 27121505
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
Habbous S; Przech S; Martin J; Garg AX; Sarma S
Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of sevelamer in patients with end-stage renal disease.
Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
[TBL] [Abstract][Full Text] [Related]
7. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
[TBL] [Abstract][Full Text] [Related]
9. A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients.
Cho JH; Jang HM; Jung HY; Choi JY; Park SH; Kim CD; Yang CW; Jin DC; Kim YL
Clin Ther; 2018 Jan; 40(1):123-134. PubMed ID: 28291581
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
Covic AC; Sprague SM; Rastogi A; Ketteler M; Walpen S; Perrin A; Floege J
Nephron; 2020; 144(9):428-439. PubMed ID: 32585670
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
[TBL] [Abstract][Full Text] [Related]
12. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
[TBL] [Abstract][Full Text] [Related]
13. An economic evaluation of sevelamer in patients new to dialysis.
Taylor MJ; Elgazzar HA; Chaplin S; Goldsmith D; Molony DA
Curr Med Res Opin; 2008 Feb; 24(2):601-8. PubMed ID: 18205996
[TBL] [Abstract][Full Text] [Related]
14. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
Bousher A; Al-Makki A; Sutton J; Shepler B
Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
[TBL] [Abstract][Full Text] [Related]
15. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
Floege J; Covic AC; Ketteler M; Rastogi A; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
Kidney Int; 2014 Sep; 86(3):638-47. PubMed ID: 24646861
[TBL] [Abstract][Full Text] [Related]
16. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
[TBL] [Abstract][Full Text] [Related]
17. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.
Ruggeri M; Bellasi A; Cipriani F; Molony D; Bell C; Russo D; Di Iorio B
J Nephrol; 2015 Oct; 28(5):593-602. PubMed ID: 25027030
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China.
Yang L; Chuen Tan S; Chen C; Wang X; Li X; Yang X
Clin Ther; 2016 Nov; 38(11):2459-2467.e1. PubMed ID: 27751671
[TBL] [Abstract][Full Text] [Related]
19. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
Greig SL; Plosker GL
Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
Park H; Rascati KL; Keith MS; Hodgkins P; Smyth M; Goldsmith D; Akehurst R
Value Health; 2011 Dec; 14(8):1002-9. PubMed ID: 22152168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
